PBS Should Fund Triptorelin to Treat Breast Cancer, Endometriosis, and Gender Dysphoria, Experts Recommend

Source Summary

Australia's Pharmaceutical Benefits Scheme advisory committee recommends the federal government fund triptorelin, already listed for prostate cancer, for unrestricted use to treat breast cancer, endometriosis, and gender dysphoria. The urgent recommendation follows AstraZeneca's announcement to remove Zoladex from the market, which would leave over 7,500 women with breast cancer without an alternative treatment.